New research from two independent international collaborations has identified distinct molecular processes contributing to altered brain development in individuals with Down syndrome.
Both studies advance the understanding of how an extra copy of chromosome 21 influences early brain formation and function, pointing to potential targets for future therapeutic interventions.
Insights into Gene Regulation and Activity
One study, published in Nature Medicine by scientists from Duke-NUS Medical School, Imperial College London, and partners in Europe and the United States, focused on the activity of genes on chromosome 21.
Researchers identified three key genes located on chromosome 21 that act as master regulators of brain-related genetic activity. In human brain cells derived from individuals with Down syndrome, these three genes were observed to be overactive. This overactivity led to disruptions in the normal function of hundreds of other genes associated with learning and memory.
The research team explored whether these effects could be modulated using antisense oligonucleotides (ASOs), synthetic strands of genetic material designed to reduce specific gene activity.
When the activity of these three overactive genes was reduced in laboratory-grown human brain cells, a partial restoration of typical gene activity patterns was observed. This early-stage laboratory work provides a proof of concept that some molecular changes linked to Down syndrome may be biologically adjustable.
These findings also contribute to understanding how chromosome 21 may influence pathways shared with other conditions, such as Alzheimer's disease, which is more common in individuals with Down syndrome. The research team is further investigating the functional consequences of adjusting these key drivers, including their influence on brain cell growth and connection formation. A patent related to their methods has been filed, and advanced human neural models are being used to test the effectiveness of targeting specific gene combinations.
Role of RNA Editing in Early Brain Formation
A separate collaborative study, co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Lieber Institute for Brain Development, and published in Nature Communications, identified another molecular process impacting brain development in Down syndrome.
This research centered on the ADARB1 enzyme, also known as ADAR2, which plays a role in editing genetic messages within cells.
The study found that in individuals with Down syndrome, an excess of the ADARB1 enzyme leads to premature and extensive alteration of RNA messages in developing brain cells. This process, known as RNA recoding, affects how brain cells communicate and how brain circuits form. The ADARB1 gene is on chromosome 21, and its increased dosage due to trisomy 21 results in higher enzyme levels.
Researchers analyzed brain tissue collected between 13 and 22 weeks after conception, a critical period for early brain development, from 20 individuals with trisomy 21 and 27 individuals without the condition. The study focused on the prefrontal cortex and hippocampus, brain regions vital for learning and memory.
Advanced RNA sequencing revealed widespread disruption of gene expression during mid-gestation in trisomy 21, with ADARB1 being one of the most consistently over-expressed genes. Elevated ADARB1 enzyme levels correlated with increased RNA editing throughout the brain.
Excessive editing was observed in key glutamate and GABA-receptor genes, including GRIA2, GRIA3, GRIK2, and GABRA3. This alters the amino acid sequence and function of the resulting proteins, which is predicted to imbalance excitatory and inhibitory signaling during the formation of neural circuits. The findings were further supported by a combined analysis of nine independent human trisomy 21 datasets.
This study identifies ADARB1-driven RNA editing dysregulation as a fundamental molecular consequence of chromosome 21 triplication in Down syndrome. Researchers suggest that these findings could lead to new methods for measuring early brain development and inform precision treatments aimed at improving neurological and behavioral outcomes in Down syndrome.
Future Implications
Both studies contribute to a more detailed understanding of the molecular underpinnings of Down syndrome. While identifying distinct mechanisms—one focusing on master regulatory genes and another on RNA editing—both highlight the complex impact of an extra chromosome 21 on brain development. The findings from both research efforts suggest potential avenues for future investigation into therapeutic strategies, though clinical applications remain long-term goals.